What is Myriad Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Myriad Genetics's salary, the management and board of directors tenure and is there insider trading?
4.4yrs
Average management tenure
CEO
MarkCapone(57yo)
4.4yrs
Tenure
US$8,896,684
Compensation
Mr. Mark Christopher Capone has been the Chief Executive Officer and President at Myriad Genetics Inc. since July 1, 2015. Mr. Capone served as the President of Myriad Genetic Laboratories at Myriad Geneti ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD8.90M) is above average for companies of similar size in the US market ($USD3.87M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
4.4yrs
Average Tenure
52yo
Average Age
Experienced Management: MYGN's management team is considered experienced (4.4 years average tenure).
Board Age and Tenure
9.9yrs
Average Tenure
66yo
Average Age
Experienced Board: MYGN's board of directors are considered experienced (9.9 years average tenure).
Insider Trading
Insider Buying: MYGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$164,22307 Nov 19
John Henderson
Entity
Individual
Role
Chairman of the Board
Independent Chairman
Shares
7,000
Max Price
US$23.46
SellUS$61,22512 Mar 19
Ralph McDade
Entity
Individual
Shares
1,975
Max Price
US$31.00
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.
Management Team
Gary King (63yo)
Executive Vice President of International Operations
Tenure: 9.4yrs
Jerry Lanchbury (60yo)
Chief Scientific Officer
Tenure: 9.8yrs
Compensation: US$2.69m
Rishi Kacker
Chief Technology Officer
Tenure: 1.4yrs
Scott Gleason
Vice President of Investor Relations
Tenure: 0yrs
Mark Capone (57yo)
CEO, President & Director
Tenure: 4.4yrs
Compensation: US$8.90m
Ron Rogers (51yo)
Executive Vice President of Corporate Communications
Tenure: 0yrs
R. Riggsbee (48yo)
Executive VP
Tenure: 5.2yrs
Compensation: US$3.14m
Alec Ford (52yo)
President of Myriad Women’s Health
Tenure: 4.4yrs
Compensation: US$3.23m
Ben Jackson (40yo)
Executive VP
Tenure: 0.4yrs
Clivetty Martinez
Chief Compliance Officer
Tenure: 0.9yrs
Board Members
Larry Best (70yo)
Independent Director
Tenure: 10.3yrs
Compensation: US$380.49k
Wally Gilbert (87yo)
Independent Vice Chairman
Tenure: 0yrs
Compensation: US$369.99k
John Henderson (75yo)
Independent Chairman
Tenure: 14.7yrs
Compensation: US$482.49k
Dennis Langer (67yo)
Independent Director
Tenure: 15.6yrs
Compensation: US$392.49k
Lee Newcomer (66yo)
Independent Director
Tenure: 0.3yrs
Colleen Reitan (59yo)
Independent Director
Tenure: 0.3yrs
Heiner Dreismann (66yo)
Independent Director
Tenure: 9.5yrs
Compensation: US$384.99k
Mark Capone (57yo)
CEO, President & Director
Tenure: 4.4yrs
Compensation: US$8.90m
S. Phanstiel (61yo)
Independent Director
Tenure: 10.3yrs
Compensation: US$399.49k
Company Information
Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing  ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/05 23:40
End of Day Share Price
2019/12/05 00:00
Earnings
2019/09/30
Annual Earnings
2019/06/30
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.